Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
After Novartis and Ionis Pharmaceuticals reported that pelacarsen failed to improve cardiovascular outcomes in a late-stage test, analysts had held…
After Novartis and Ionis Pharmaceuticals reported that pelacarsen failed to improve cardiovascular outcomes in a late-stage test, analysts had held…